ProPrep™ Genomic XL_2
- Known as:
- ProPrep™ Genomic XL_2
- Catalog number:
- PBKXL-2
- Product Quantity:
- 2, 10ml whole blood
- Category:
- -
- Supplier:
- Biotech support group
- Gene target:
- ProPrep™ Genomic XL_2
Related genes to: ProPrep™ Genomic XL_2
- Gene:
- APEX2 NIH gene
- Name:
- apurinic/apyrimidinic endodeoxyribonuclease 2
- Previous symbol:
- -
- Synonyms:
- APEXL2, APE2, XTH2, ZGRF2
- Chromosome:
- Xp11.21
- Locus Type:
- gene with protein product
- Date approved:
- 2002-07-22
- Date modifiied:
- 2016-10-05
- Gene:
- FBXL21P NIH gene
- Name:
- F-box and leucine rich repeat protein 21, pseudogene
- Previous symbol:
- FBXL3B, FBXL3P, FBXL21
- Synonyms:
- FBL3B, Fbl21
- Chromosome:
- 5q31.1
- Locus Type:
- pseudogene
- Date approved:
- 2000-09-27
- Date modifiied:
- 2018-10-24
- Gene:
- GPX1P1 NIH gene
- Name:
- glutathione peroxidase pseudogene 1
- Previous symbol:
- GPXL2, GPXP1
- Synonyms:
- -
- Chromosome:
- Xp22.2
- Locus Type:
- pseudogene
- Date approved:
- 1988-07-25
- Date modifiied:
- 2014-11-19
- Gene:
- GPX1P2 NIH gene
- Name:
- glutathione peroxidase pseudogene 2
- Previous symbol:
- GPXL1, GPXP2
- Synonyms:
- GPXL2, GPXP2P
- Chromosome:
- 21q21.3
- Locus Type:
- pseudogene
- Date approved:
- 1988-07-25
- Date modifiied:
- 2014-11-19
- Gene:
- PCNX2 NIH gene
- Name:
- pecanex 2
- Previous symbol:
- PCNXL2
- Synonyms:
- KIAA0435, FLJ11383
- Chromosome:
- 1q42.2
- Locus Type:
- gene with protein product
- Date approved:
- 1998-10-12
- Date modifiied:
- 2018-06-21
Related products to: ProPrep™ Genomic XL_2
Related articles to: ProPrep™ Genomic XL_2
- DLBCL is the most common type of non-Hodgkin lymphoma with a substantial group of patients suffering a poor prognosis. Therefore more specific markers are required for better understanding of disease biology and treatment. This study demonstrates that testis-specific antioxidant enzymes TXNDC2, TXNDC3, and TXNDC6 alongside oxidative stress marker 8-OHdG are expressed in both testicular and systemic DLBCL, and their presence or absence has correlations with clinical risk factors such as the number of extranodal effusion, the appearance of B-symptoms, and treatment response. Biopsy samples were collected from 28 systemic and 21 testicular male DLBCL patients. The samples were histostained with TXNDC2, TXNDC3, TXNDC6, and 8-OHdG, then graded by a hematopathologist blinded to clinical data. Immunoelectron microscopy was used as a second method to confirm the reliability of the acquired immunohistochemistry data. The absence of nuclear TXNDC2 expression in testicular DLBCL cells correlated with worse primary treatment response, cytoplasmic TXNDC3 expression in testicular and systemic DLBCL associated with lower frequency of B-symptoms, and TXNDC6 expression in cytoplasm in systemic DLBCL had a clinical significance with higher LD levels suggesting a role in the biological nature of these lymphomas. Overall, TXNDC3 cytoplasmic expression is correlated with a more positive outcome in both testicular and systemic DLBCL, while TXNDC6 cytoplasmic expression is associated with a negative outcome in systemic DLBCL. - Source: PubMed
Publication date: 2021/02/01
Chan Mikko CSavela JanetteOllikainen Riina KTeppo Hanna-RiikkaMiinalainen IlkkaPirinen RistoKari Esa J MKuitunen HanneTurpeenniemi-Hujanen TainaKuittinen OutiKuusisto Milla E L - The Nme gene/protein family of nucleoside diphosphate kinases (NDPK) was originally named after its member Nm23-H1/Nme1, the first identified metastasis suppressor. Human Nme proteins are divided in two groups. They all possess nucleoside diphosphate kinase domain (NDK). Group I (Nme1-Nme4) display a single type NDK domain, whereas Group II (Nme5-Nme9) display a single or several different NDK domains, associated or not associated with extra-domains. Data strongly suggest that, unlike Group I, none of the members of Group II display measurable NDPK activity, although some of them autophosphorylate. The multimeric form is required for the NDPK activity. Group I proteins are known to multimerize, while there are no data on the multimerization of Group II proteins. The Group II ancestral type protein was shown to be conserved in several species from three eukaryotic supergroups. Here, we analysed the Nme protein from an early branching eukaryotic lineage, the red alga . We show that the ancestral type protein, unlike its human homologue, was fully functional multimeric NDPK with high affinity to various types of DNA and dispersed localization throughout the eukaryotic cell. Its overexpression inhibits both cell proliferation and the anchorage-independent growth of cells in soft agar but fails to deregulate cell apoptosis. We conclude that the ancestral gene has changed during eukaryotic evolution, possibly in correlation with the protein function. - Source: PubMed
Publication date: 2019/12/21
Perina DragutinKorolija MarinaMikoč AndrejaHalasz MirnaHerak Bosnar MajaĆetković Helena - The Nme family, previously known as Nm23 or NDPK, is involved in various molecular processes including tumor metastasis and some members of the family, but not all, exhibit a Nucleoside Diphosphate Kinase (NDPK) activity. Ten genes are known in humans, in which some members have been extensively studied. In non-mammalian species, the Nme protein family has received, in contrast, far less attention. The picture of the vertebrate Nme family remains thus incomplete and orthology relationships with mammalian counterparts were only partially characterized. The present study therefore aimed at characterizing the Nme gene repertoire in vertebrates with special interest for teleosts, and providing a comprehensive overview of the Nme gene family evolutionary history in vertebrates. - Source: PubMed
Publication date: 2009/10/23
Desvignes ThomasPontarotti PierreFauvel ChristianBobe Julien - The delta opioid antagonist H-Dmt-Tic-OH (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) exhibits extraordinary delta receptor binding characteristics [Ki delta = 0.022 nM; Ki mu/Ki delta = 150,000] and delta antagonism (pA2 = 8.2; Ke = 5.7 nM). A change in chirality of Dmt at C alpha (1, 2, 6, 8, 10, 13) curtailed delta receptor parameters, while replacement of its alpha-amino function by a methyl group (3) led to inactivity; Tyr-Tic analogues 4 and 11 weakly interacted with delta receptors. N-Alkylation of H-Dmt-Tic-OH and H-Dmt-Tic-Ala-OH with methyl groups produced potent delta-opioid ligands with high delta receptor binding capabilities and enhanced delta antagonism: (i) N-Me-Dmt-Tic-OH 5 had high delta opioid binding (Ki delta = 0.2 nM), elevated delta antagonism on mouse vas deferens (MVD) (pA2 = 8.5; Ke = 2.8 nM), and nondetectable mu activity with guinea pig ileum (GPI). (ii) N,N-Me2-Dmt-Tic-OH (12) was equally efficacious in delta receptor binding (Ki delta = 0.12 nM; Ki mu/Ki delta = 20000), but delta antagonism rose considerably (pA2 = 9.4; Ke = 0.28 nM) with weak mu antagonism (pA2 = 5.8; Ke = 1.58 microM; GPI/MVD = 1:5640). N-Me-(9) and N,N-Me2-Dmt-Tic-Ala-OH (15) also augmented delta opioid receptor binding, such that 15 demonstrated high affinity (Ki delta = 0.0755 nM) and selectivity (Ki mu/Ki delta = 20132) with exceptional antagonist activity on MVD (pA2 = 9.6; Ke = 0.22 nM) and weak antagonism on GPI (pA2 = 5.8; Ke = 1.58 microM; GPI/MVD = 1:7180). Although the amidated dimethylated dipeptide analogue 14 had high Ki delta (0.31 nM) and excellent antagonist activity (pA2 = 9.9; Ke = 0.12 nM), the increased activity toward mu receptors in the absence of a free acid function at the C-terminus revealed modest delta selectivity (Ki mu/Ki delta = 1655) and somewhat comparable bioactivity (GPI/MVD = 4500). Thus, the data demonstrate that N,N-(Me)2-Dmt-Tic-OH (12) and N,N-Me2-Dmt-Tic-Ala-OH (15) retained high delta receptor affinities and delta selectivities and acquired enhanced potency in pharmacological bioassays on MVD greater than that of other peptide or non-peptide delta antagonists. - Source: PubMed
Salvadori SBalboni GGuerrini RTomatis RBianchi CBryant S DCooper P SLazarus L H